CPX-351 in higher risk myelodysplastic syndrome and chronic myelomonocytic leukaemia: a multicentre, single-arm, phase 2 study

医学 内科学 阿糖胞苷 队列 慢性粒单核细胞白血病 骨髓增生异常综合症 移植 背景(考古学) 外科 肿瘤科 白血病 骨髓 生物 古生物学
作者
Pierre Péterlin,Yannick Le Bris,Pascal Turlure,Patrice Chevallier,Audrey Ménard,Marie-Pierre Gourin,Pierre‐Yves Dumas,Sylvain Thépot,Ana Berceanu,Sophie Park,Marie‐Anne Hospital,Thomas Cluzeau,Simon Bouzy,Jose-Miguel Torregrosa-Diaz,Louis Drevon,Rosa Sapena,Fatiha Chermat,Lionel Adès,Sophie Dimicoli‐Salazar,Sylvie Chevret
出处
期刊:The Lancet Haematology [Elsevier BV]
卷期号:10 (7): e521-e529 被引量:19
标识
DOI:10.1016/s2352-3026(23)00090-x
摘要

CPX-351, an encapsulated form of cytarabine and daunorubicin, has shown greater efficacy than the classic 3 + 7 treatment administration in secondary acute myeloid leukaemia. Given that higher-risk myelodysplastic syndrome and chronic myelomonocytic leukaemia share similarities with secondary acute myeloid leukaemia, we aimed to investigate the safety and efficacy of CPX-351 in this context.This investigator-initiated two-cohort phase 2 trial was conducted by the Groupe Francophone des Myélodysplasies, with 12 participating centres in France. It comprised cohort A (reported here and completed), which included patients in first-line treatment, and cohort B, which was stopped for lack of inclusion (ie, not enough patients met the inclusion criteria), for patients with hypomethylating agent failure that is not reported here. Cohort A enrolled patients with newly diagnosed higher-risk myelodysplastic syndrome or chronic myelomonocytic leukaemia (aged 18-70 years old) with an Eastern Cooperative Oncology Group performance status of 0-1. Intravenous CPX-351 (100 mg/m2 cytarabine and 44 mg/m2 daunorubicin) was given on days 1, 3, and 5, with a second induction cycle given (same daily dose on days 1 and 3) if at least a partial response was not reached. Patients who responded could receive up to four monthly consolidation cycles (same daily dose on day 1) or allogeneic haematopoietic stem-cell transplantation (HSCT). Overall response rate after one or two induction courses according to European LeukemiaNet 2017 acute myeloid leukaemia was the primary endpoint after CPX-351 induction, whether patients received one or two induction cycles. Safety was assessed in all patients enrolled (in cohort A). This trial is registered with ClinicalTrials.gov, NCT04273802.Between April 29, 2020, and Feb 10, 2021, 21 (68%) male and ten (32%) female patients were enrolled. 27 (87%) of 31 patients responded (95% CI 70-96). 16 (52%) of the 31 patients received at least one consolidation cycle. 30 (97%) of the 31 patients included were initially considered eligible for allogeneic HSCT and 29 (94%) of the 31 patients had the procedure. Median follow-up was 16·1 months (IQR 8·3-18·1). The most common grade 3-4 adverse events were pulmonary (eight [26%] of 31 patients) and cardiovascular (six [19%] of 31 patients). There were 14 serious adverse events (mainly hospitalisation for infection [n=5] and only one was treatment-related) and no treatment-related death.CPX-351 appears to be active and safe in patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukaemia, allowing bridging to allogenic HSCT in most patients.Jazz Pharmaceuticals.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
MMZ完成签到 ,获得积分10
3秒前
qianlan发布了新的文献求助10
3秒前
yemeiyu完成签到,获得积分10
4秒前
凶狠的谷蓝完成签到,获得积分10
4秒前
rzzzz完成签到,获得积分20
4秒前
Future发布了新的文献求助10
4秒前
Yue发布了新的文献求助10
5秒前
科研小桶发布了新的文献求助10
6秒前
18°N天水色完成签到,获得积分10
7秒前
7秒前
zpy完成签到,获得积分10
8秒前
dddd完成签到,获得积分10
8秒前
许哲完成签到,获得积分10
9秒前
9秒前
qianlan完成签到,获得积分10
9秒前
9秒前
汉堡包应助yff采纳,获得10
10秒前
11秒前
王嘉玮发布了新的文献求助10
11秒前
浅斟低唱发布了新的文献求助10
14秒前
斯文败类应助姜姜采纳,获得10
14秒前
豌豆射手发布了新的文献求助30
16秒前
科研小桶完成签到,获得积分20
20秒前
Lisa完成签到 ,获得积分10
20秒前
bogula1112完成签到 ,获得积分10
23秒前
ysysljj应助科研通管家采纳,获得10
25秒前
李爱国应助科研通管家采纳,获得10
25秒前
慕青应助科研通管家采纳,获得20
25秒前
ysysljj应助科研通管家采纳,获得30
25秒前
NexusExplorer应助科研通管家采纳,获得10
25秒前
今后应助科研通管家采纳,获得10
25秒前
25秒前
25秒前
25秒前
小蘑菇应助聪慧的盼夏采纳,获得10
26秒前
白白完成签到 ,获得积分10
27秒前
王嘉玮完成签到,获得积分10
28秒前
Bio应助www采纳,获得30
28秒前
28秒前
高分求助中
【重要!!请各位用户详细阅读此贴】科研通的精品贴汇总(请勿应助) 10000
Genomic signature of non-random mating in human complex traits 2000
Semantics for Latin: An Introduction 1099
醤油醸造の最新の技術と研究 1000
Plutonium Handbook 1000
Three plays : drama 1000
Robot-supported joining of reinforcement textiles with one-sided sewing heads 640
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4109721
求助须知:如何正确求助?哪些是违规求助? 3648056
关于积分的说明 11555522
捐赠科研通 3353801
什么是DOI,文献DOI怎么找? 1842442
邀请新用户注册赠送积分活动 908829
科研通“疑难数据库(出版商)”最低求助积分说明 825745